English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/76970
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease

AuthorsMorales-García, José A. ; Susín, Cristina ; Alonso-Gil, Sandra ; Pérez, Daniel I.; Palomo Ruiz, Valle; Pérez, Concepción; Conde, Santiago ; Santos, Ángel; Gil, Carmen ; Martínez, Ana ; Pérez Castillo, Ana
Issue Date2013
PublisherAmerican Chemical Society
CitationACS Chemical Neuroscience 4(2): 350-360 (2013)
AbstractParkinson's disease (PD) is a devastating neurodegenerative disorder characterized by degeneration of the nigrostriatal dopaminergic pathway. Because the current therapies only lead to temporary, limited improvement and have severe side effects, new approaches to treat PD need to be developed. To discover new targets for potential therapeutic intervention, a chemical genetic approach involving the use of small molecules as pharmacological tools has been implemented. First, a screening of an in-house chemical library on a well-established cellular model of PD was done followed by a detailed pharmacological analysis of the hits. Here, we report the results found for the small heterocyclic derivative called SC001, which after different enzymatic assays was revealed to be a new glycogen synthase kinase-3 (GSK-3) inhibitor with IC50 = 3.38 ± 0.08 μM.To confirm that GSK-3 could be a good target for PD, the evaluation of a set of structurally diverse GSK-3 inhibitors as neuroprotective agents for PD was performed. Results show that inhibitors of GSK-3 have neuroprotective effects in vitro representing a new pharmacological option for the disease-modifying treatment of PD. Furthermore, we show that SC001 is able to cross the blood-brain barrier, protects dopaminergic neurons, and reduces microglia activation in in vivo models of Parkinson disease, being a good candidate for further drug development. © 2012 American Chemical Society.
Publisher version (URL)http://dx.doi.org/10.1021/cn300182g
URIhttp://hdl.handle.net/10261/76970
DOI10.1021/cn300182g
Identifiersdoi: 10.1021/cn300182g
issn: 1948-7193
Appears in Collections:(IQM) Artículos
(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.